Dr. Leiderman is a seasoned biotech leader with 20 years experience at the intersection of medical innovation and healthcare investment banking. She excels in fundraising, capital structure, financial analysis, and valuation. During her dynamic career, she has supported the growth of life science organizations such as Bluebird Bio, Autolus Therapeutics, Atsena Therapeutics where she raised $32M in series B, Decibel Therapeutics for which she led a $125M IPO and $82M series D, Complexa and Fortress Biotech. Her M&A and business development skills include corporate growth strategies, opportunity analysis, due diligence, and transaction leadership.